Tumor immunotherapy is a hotspot in current and future research, and T cell immunoglobulin mucin 3 (TIM3) is another emerging immune checkpoint molecule after PD-1/PD-L1 and CTLA-4 [32]. This evidence concerns the gene HAVCR2 and neoplasm.